Accessibility Menu
 

FDA Accepts Application for Bristol-Myers Squibb and bluebird bio's Multiple Myeloma CAR-T Therapy

The Food and Drug Administration's acceptance means it will issue a go/no-go decision on ide-cel in March 2021.

By Todd Campbell Sep 22, 2020 at 1:20PM EST

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.